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Abstract
Background—The Institute of Medicine (IOM) has recommended that each person with cancer
should have access to clinical trials, which have been associated with improving care quality and
disparities. With no effective enrollment monitoring system, patterns of trial enrollment remain
unclear.
Purpose—We developed a population-based, statewide system designed to facilitate monitoring
of cancer trial enrollment and targeting of future interventions to improve it.
Methods—Person-level cancer incidence data from the North Carolina Central Cancer Registry
(NCCCR), person-level treatment trial accrual data from the National Cancer Institute (NCI), and
county-level Area Resource Files (ARF) measures for 12 years, 1996–2007, were studied. De-
identified person-level data necessitated county-level analysis. Enrollment rates were estimated as
the ratio of trial enrollment to cancer incidence for each race, gender, year, and county
combination. Multivariable analysis examined factors associated with trial accrual. Sensitivity
analyses examined spurious fluctuations and temporal discordance of incidence and enrollment.
Results—The NCI treatment trial enrollment rate was 2.39% for whites and 2.20% for minorities
from 1996 to 2007, and 2.88% and 2.47%, respectively, for 2005–2007. Numerous counties had
no minority enrollment. The 2005–2007 enrollment rates for white and minority females was
4.04% and 3.59%, respectively, and for white and minority males was 1.74% and 1.36%,
respectively. Counties with a medical school or NCI Community Clinical Oncology Program
(CCOP)-affiliated practice had higher trial enrollment.
Limitations—We examined NCI trial accrual only – industry-sponsored and investigator-
initiated trials were excluded; however, NCI studies comprise the majority of all clinical trial
participants. Delays in data availability may hinder immediacy of population-based analyses.
Conclusions—Model stability and consistency suggest this system is effective for population-
based enrollment surveillance. For North Carolina, it suggests a worsening disparity in minority
trial enrollment, though our analyses elucidate targets for intervention. Regional enrollment
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variation suggests the importance of access to clinical research networks and infrastructure.
Substantial gender differences merit further examination.
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Introduction
Randomized controlled trials are a central driver of research discovery and advances in
cancer care, and the gold standard in assessing efficacy of new cancer interventions.1
Treatment efficacy increasingly hinges on specific genotypes that may be expressed in only
a limited subset of the population; thus, enhanced and expanded trial inclusion of diverse
populations is needed to develop broadly-effective treatments.2 At the same time, it is
widely believed that clinical trials are a conduit for communicating new developments in
high-quality state-of-the-art care, and a vehicle for accelerating the dissemination of
evidence-based discoveries into practice.2–5 Academic medical centers (AMCs) have long-
served as the major hubs of clinical research; however, less than one percent of Americans
seek their care from AMCs, representing both a bottleneck in clinical trial access and an
impediment to bridging the discovery-delivery gap.6, 7
For these reasons and others, the Institute of Medicine (IOM) has recommended that each
person with cancer should have access to high quality clinical trials. The National Institutes
of Health (NIH) has invested heavily in provider-based research networks (PBRNs) through
the Roadmap.8–12 PBRNs provide critical research infrastructure opening access and
facilitating clinical trial enrollment outside of AMCs in the community, where the majority
of cancer patients seek treatment.2, 9 The National Cancer Institute’s Community Clinical
Oncology Program (CCOP) and Minority-Based Community Clinical Oncology Program
(MBCCOP) are cancer-focused PBRNs.2 The North Carolina Comprehensive Cancer
Program (NC-CCP) and many other state cancer control programs have embraced this
guidance and are moving to address goals relating to trial enrollment. .13–15 For North
Carolina, improving access to clinical trials is part of a multi-part strategy to optimize cancer
outcomes for all North Carolinians, with a particular emphasis on resolving profound racial
disparities: In North Carolina, African Americans experience cancer-specific mortality that
ranges from 25% to an astounding 2.6 times greater than that of whites for the most common
cancers.16, 17
Despite such interest, advocacy, and investment, there is exceptionally little empirical
information and no practical system for these programs to understand how enrollment may
differ by geographic region, race, or other characteristics amenable to interventions to
increase enrollment. Meanwhile, it is estimated nationally that fewer than 5% of the adult
cancer population receives treatment through an NCI-sponsored clinical trial, and among
minorities, enrollment estimates are even lower and appear to be declining18–21. In North
Carolina, these percentage estimates are unknown. We describe a novel statewide system for
ongoing monitoring and public reporting of NCI clinical trial enrollment developed to
extend clinical trials access to broader patient populations. We articulate our methods so
they may be replicated in other states.
Methods
Person-level cancer incidence data were obtained from the NC Central Cancer Registry
(CCR) for years 1996–2007. Person-level NCI clinical trial accrual data were obtained from
the NCI Cancer Therapy Evaluation Program (CTEP) through a Freedom of Information Act
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request. From both data sets, variables included age at diagnosis/enrollment, gender, race,
ethnicity, county of residence, and cancer type. From CTEP, data also included protocol
number, protocol name, study phase (e.g., I–III), and NIH administration code. Using
descriptive data from CTEP, the Physician PDQ, ClinicalTrials.gov, and caCORE, trials
were categorized according to their primary intent: treatment, prevention/early detection,
symptom/side-effect control, diagnostic, or "other."22–24 Select socioeconomic and regional
health care organization data were obtained from Area Resource Files.25 Locations of NCI
Community Clinical Oncology Program (CCOP)-affiliated community practices were
obtained from the Southeast Cancer Control Consortium.26, 27
The primary goal was to inform the development of a new trial enrollment monitoring
system; thus, analysis was primarily descriptive in nature and focused on variation and
stability of treatment trial enrollment measures among adults aged 21 and older. There was
insufficient information on personal identifiers, to allow linking the datasets at the person-
level; thus, the data were pooled and analyzed at the county-level. Minority status was
defined only by race because ethnicity data from CTEP and CCR were incomplete. Trial
accrual rate estimates were calculated by dividing the count of annual enrollment by the
count of newly incident cases for each race, gender, county, and year combination. Three-
year averages were used to mitigate spurious fluctuations resulting from sparse data for
several counties and race-gender combinations. Univariate and bivariate trend analysis were
conducted for the entire study period and, to understand trend changes, for the most current
three years (2005–2007). Extensive sensitivity analyses examined temporal parity between
year of incident diagnosis and trial enrollment, and variation in enrollment by trial phase
based on the assumptions that (a) enrollment may or may not occur in the same year as
diagnosis, and (b) compared to Phase III enrollment, Phase I enrollment may less often
occur in the same year as diagnosis, perhaps as patients exhaust mainstream therapies. We
used Pearson chi-square tests to examine variable distributions between cancer incidence
and trial enrollment and by in-county presence of a CCOP-affiliated practice or a medical
school.
A limited analytic model assessed feasibility of multivariable analysis for predictors
associated with trial accrual. Because data are structured at the county-level and the
dependent variable (accrual rate) is binomially distributed, analysis included a repeated
measures approach (Proc Glimmix) using race and gender combinations in SAS (9.2). This
modeling approach assumes that each race and gender combination is sampled from the
same population and any effects (log-linear odds) over time within this sampling unit are
constant. This approach is analogous to having a cohort of 400 (100 counties × 4 race/
gender combinations), each of which has a random slope and intercept, with all covariates in
the model (AHEC, CCOP, etc) considered to be fixed effects. Model parameters are
estimates of log odds associated with each covariate at the county level.
Results
Between 1996 and 2007, 479,123 adults were diagnosed with cancer in NC; 11,362 adults
enrolled in NCI-sponsored treatment trials, yielding an estimated overall enrollment rate of
2.37% (Table 1). The average age at diagnosis was 65.0, and the average age at trial
enrollment was 57.8. The proportion of women who enrolled in trials was approximately
twice that of men (3.20% vs. 1.55%). Minority men had the lowest enrollment rate at 1.33%
(OR 0.84 95% CI 0.77–0.92, compared to white men), while the enrollment rate of white
women was highest at 3.21% -- 2.4 times higher than minority men. In recent years
enrollment rates among all races and genders increased except among minority men (1.36%
- data not shown).
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Counties with NCI CCOP-affiliated practices and medical schools typically had greater
enrollment (Table 2). The average enrollment rate among counties with a CCOP practice
was 2.68% -- 25% greater than non-CCOP/medical school counties. Similarly, average
enrollment in counties with a medical school was 2.87% -- 34% greater than non-CCOP/
medical school counties. The county-level proportion of uninsured was inversely related to
county-level enrollment (OR 0.81, 95% CI 0.77–0.86).
Counties with a CCOP or a medical school tended to have a greater proportion of minorities.
In CCOP counties, 18.78% of the clinical trial population was composed of minorities, a
comparable percentage to the 19.02% of the incident cancer population composed of
minorities in CCOP counties (Table 2). The ratio of these percentages reflects the
comparable proportionality of minorities in these groups: 0.987. In medical school counties
minorities represented 24.64% of trial enrollment and 25.98% of incident cancer (ratio: .
948). In all other counties, minorities represented 17.14% of trial enrollment and 18.73% of
incident cancer (ratio: .915). Differences in enrollment by gender were comparable among
CCOP, medical school, and all other counties.
Figure 1 presents enrollment over time represented by 3-year averages. Overall, enrollment
increased slightly over time, though more-so and more consistently among whites than
among minorities (7.9% vs. 2.9%, respectively). The average enrollment rate was highest in
the most recent 3-year period at 2.9% among whites, and 2.5% among minorities. Figure 2
presents county-level estimated enrollment rates by race from 2005 to 2007 and indicates the
location of CCOP practices and medical schools. In Figure 2, and in Figure 3 in which
counties have been grouped into regions, we see wide geographic variation in enrollment
rates, including no enrollment among minorities in multiple counties.
In a limited multivariable analysis, having a CCOP in the county was associated with
substantially greater accrual rate (OR 1.51, 95% CI: 1.10–2.08) (Table 3). Having a medical
school in the county tended to to increase accrual (OR 1.14, 95% CI: 0.68–1.9). Local
insurance coverage was relevant, as counties with the smallest proportion of uninsured
tended to have greater clinical trial enrollment (OR 1.53, 95% CI: 1.03–2.27). Enrollment in
clinical trials increased over time (OR 1.08, 95% CI: 1.04–1.12), supporting the trend shown
in Figure 1.
Based on sensitivity analyses, the enrollment estimates and trends were consistent between
Phase III and overall enrollment, with overall enrollment rates slightly greater though
consistently in-parallel with trends in Phase III trial enrollment rates. Contemporaneous and
time-lagged estimates were similar, as were estimates using two-year and three-year moving
averages, though three-year estimates were more smoothed, as expected. (Data not
presented).
Discussion
The goal of this study was to develop a statewide system for ongoing monitoring and public
reporting of NCI clinical treatment trial enrollment. This system builds upon the work of
prior studies, which had many strengths, but also limitations including use of self-report of
trial participation,28 estimates of cancer burden,29 data from a single institution,30 or data
from a limited number of years.28, 31 This system has used actual state-wide population-
based data on clinical trials participation from the NCI, and cancer incidence data from the
North Carolina Central Cancer Registry spanning twelve years. It has demonstrated good
consistency through rigorous sensitivity analyses, suggesting stability and utility in
measuring trial enrollment rates over time. Our analyses revealed a modest increase in
enrollment over time, though with substantial variation by gender and race. Men enrolled in
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trials at less than half the rate of women. Minority men had the lowest enrollment rate,
enrolling at a significantly lower rate than white men. Geographic variation was evident,
with the highest accrual rates in counties with a medical school or CCOP practice.
The finding that counties with a medical school or CCOP had higher enrollment rates points
to the importance of access to these research resources with regard to both overall
enrollment and attenuation of racial enrollment disparities. The importance of CCOPs is
likely even greater than suggested here, since several CCOP practices serve multiple
counties. For example, in the south-central region of the state, one CCOP practice is a
referral center for a multi-county area, as demonstrated in the elevated clinical trial
enrollment rates in the contiguous non-CCOP counties. This observation highlights the fact
that health care is largely a local phenomenon, and without clinical trials networks and
outreach programs, a large proportion of the North Carolina population would have no
access to NCI clinical trials. It also speaks to the greater issue of health care disparities and
differences in access to primary and specialty care. In North Carolina, the areas of low trial
enrollment roughly correspond to those areas experiencing the greatest racial health
disparities and challenges with health care access. This finding calls for future research to
model geographic clustering more extensively than was possible within the scope of this
study. The wide variation in enrollment by county also suggests merit in more extensive
examination of additional factors that may be associated with enrollment.
Gender differences in enrollment speak to the relevance of not only geographic access, but
also access in terms of trials and inclusion criteria relevant for men. The data in this study
include accrual for 29 breast cancer trials, but only 17 prostate cancer trials in the year 2007.
A current review of ClinicalTrials.gov reflects a similarly disproportionate picture.32 Lower
enrollment rates among men thus may be in part due to the relative dearth of prostate cancer
studies, restrictive inclusion criteria, and possibly men’s comparative lack of awareness or
understanding of cancer trials.33, 34 Further examination of gender disparities in clinical
trials enrollment is warranted, and may involve examination of more inherently sociological
issues including men’s health care communication, care seeking behaviors, and perceptions
of clinical trials.
This preliminary examination empirically has documented racial disparities in trial
enrollment at the population-level and points to opportunities for intervention. Specifically,
racial disparities appear to be associated with both gender and proximity to clinical research
infrastructure. Thus, the perception of health care as a local phenomenon appears to be
particularly true for minorities in North Carolina. This finding substantiates the NCI’s
significant investment in resolving cancer health disparities by extending clinical trials
outside academic centers into the community. Several NCI programs are designed to support
research networks facilitating clinical trials access and cutting edge cancer care delivery
among medically underserved populations, including the Cancer Disparities Research
Partnership (CDRP) Program, the Community Networks Program (CNP), the Community
Clinical Oncology Program (CCOP), the Minority-Based CCOP (MB-CCOP) and the
Community Cancer Centers Program (NCCCP).2, 23, 35–37 This study lends empirical
support to the long anecdotally observed effectiveness of these programs.5, 38
Among design considerations, first, there is not always temporal concordance between
cancer incidence and trial enrollment, and such temporal alignment may differ among phase
I, phase II, and phase III trials. Extensive sensitivity analyses examined enrollment for each
phase of trial individually and collectively, including scenarios of temporal concordance
(enrollment in same year as incidence), one-year lagged enrollment, and two-year lagged
enrollment. This model was found to be consistently stable. While point estimates varied
slightly, three-year averages and time trends were consistent, pointing to reliability of this
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approach for ongoing surveillance and monitoring. Second, as is standard among cancer
registries, the NC CCR delays the release of data to researchers to assure complete case
ascertainment before doing so. This delay may impede the timeliness of monitoring
interventions designed to increase enrollment. However, the NCI trial data remain more
current. Future research may examine the stability of these data alone and their independent
utility for reporting to meet basic monitoring needs prior to availability of concurrent CCR
data. Third, and very importantly, these data were examined at the county-level due to data
use restrictions. Future analyses using person-level linked data and more granular
geographic units would be much more informative and yield findings that are much more
conducive to intervention. Thus, the goal of obtaining and examining person-level linked
data remains significant. Finally, because this study examines North Carolina, its
generalizability may be limited; however, these methods can be used by researchers to
estimate trial enrollment rates in other states. Replication using national cancer registry data
from the National Cancer Institute and Centers for Disease Control and Prevention35, 39
would allow nationwide estimates of county-level clinical trial enrollment.
This system was developed to track participation in NCI-sponsored cancer clinical trials.
Comprehensive enrollment data on investigator-initiated and industry trials are exceedingly
difficult to obtain, in large part due to their fragmented and often proprietary nature, which
explains why enrollment rates in non-NCI trials nationally remains unknown. It is believed
that most treatment trial enrollment is through NCI-sponsored trials; however, non-NCI
trials tend to be early-phase trials whereas NCI trials are more often large-population Phase
III trials.12 Future research should examine non-NCI trials access to and enrollment in
smaller, early-phase industry-sponsored and investigator initiated trials remains important.
As cancer care becomes increasingly personalized, the need for heterogeneous enrollment is
essential to the generalizability of trial results. Participation by patients from all
subpopulations is needed if all are to benefit from advances in cancer research. With no
population-based system for tracking trial enrollment, and no registry integrating both
incidence and enrollment details, the system described here was developed collaboratively
as a part of the NC-CCP, the Carolina Community Network (the NCI CNP in North
Carolina), and the University of North Carolina’s University Cancer Research Fund
(UCRF).15, 17, 36 A goal of these groups is to optimize cancer outcomes for North
Carolinians, and so this system will be integrated into its Integrated Cancer Information and
Surveillance System (ICISS)17, 40 for communicating with stakeholders and ongoing
reporting of practical information for targeting interventions to increase enrollment,
particularly among underserved and low-access populations. It is fully anticipated that this
system will provide the same utility for other state systems pursuing these goals.
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Trends in NCI Treatment Trial Enrollment Rates in North Carolina, by Race; 3-year
averages, 1996–2007
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Geographic and racial variation in NCI treatment trial enrollment in North Carolina, by
county, 2005–2007.
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Geographic and racial variation in NCI treatment trial enrollment in North Carolina, by
AHEC Region, 2005–2007.
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Table 3
County-level factors associated with NCI treatment trial enrollment rates.
County Characteristic OR 95% CI
CCOP practice in county 1.51 (1.10 – 2.08)
Medical School in county 1.14 (0.68 – 1.90)
Uninsured population -
  Quartile 1: Fewest Uninsured 1.53 (1.03 – 2.27)
  Quartile 2: Few Uninsured 1.16 (0.82 – 1.65)
  Quartile 3: More Uninsured 0.93 (0.68 – 1.28)
  Quartile 4: Most Uninsured (ref)
Region of the state (AHEC region)
  AHEC Area L 1.00 (0.57 – 1.76)
  AHEC Charlotte 0.92 (0.59 – 1.44)
  AHEC Eastern 0.81 (0.54 – 1.20)
  AHEC Greensboro 1.19 (0.77 – 1.85)
  AHEC Mountain 0.97 (0.66 – 1.42)
  AHEC Wake 0.80 (0.51 – 1.25)
  AHEC Southeast 0.77 (0.43 – 1.39)
  AHEC Southern 0.83 (0.51 – 1.35)
  AHEC Northwest (ref)
Time (Year) 1.08 (1.04 – 1.12)
CCOP: Community Clinical Oncology Program; AHEC: Area Health Education Center AHEC Regions are presented in Figure 3.
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